June 01, 2016
1 min read
Save

Significant increase seen in weighted average regional, segmental lordosis following MIS interbody fusion

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Results from this literature review showed that following minimally invasive interbody fusion, there were significant gains in weighted average lumbar lordosis and segmental lordosis.

Researchers performed a literature review through a search of MEDLINE and Google Scholar databases and found 23 articles on alignment following minimally invasive lumbar fusion for degenerative lumbar spinal conditions. Search terms included terms such as, lordosis, minimally invasive, interbody, fusion and cervical. Changes in alignment between preoperative and postoperative measures were calculated for 28 study groups with matched data to determine differences after intervention.

Results showed procedural groups included minimally invasive surgery (MIS) anterior lumbar interbody fusion, extreme lateral interbody fusion and MIS posterior/transforaminal lumbar interbody fusion. Investigators noted the weighted average of lumbar lordosis preoperatively across the 19 lumbar lordosis cohorts and 720 patients was 43.5° and postoperatively it increased 3.4°.

According to researchers, the segmental lordosis increased from a weighted average of 8.3° preoperatively to 11.2° postoperatively in 24 study groups with a total of 1,182 patients.

“Simple linear regression revealed a significant relationship between preoperative lumbar lordosis and change in lumbar lordosis (r2=0.413; P=0.003), wherein lower preoperative lumbar lordosis predicted a greater increase in postoperative lumbar lordosis,” the authors wrote. ‒ by Monica Jaramillo

 

Disclosures:  Uribe reports he receives royalties and research support, is a paid consultant, paid presenter or speaker IP and has stock options in and is member of the board or committee of Nuvasive. He also receives publishing royalties and financial or material support from Wolters Kluwer Health. Please see the full study for a list of all other authors’ relevant financial disclosures.